Advertisement
Evolus, Inc.

Evolus, Inc. (EOLS) Stock Overview

Explore Evolus, Inc.’s financial performance, market position, analyst ratings, and future outlook.

EOLSNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$6.73
$0.22(3.38%)
U.S. Market opens in 53h 40m
Advertisement

Evolus, Inc. (EOLS)

Meyka AI Score

Z

Key Financials

Market Cap443.2M
P/E Ratio-10.07
EPS (TTM)$-0.66
ROE1.75%
Fundamental Analysis

AI Price Forecasts

1 Month$4.78
3 Months$0.00
1 Year Target$0.00

EOLS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Evolus, Inc. (EOLS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 60.54, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -10.07 and a market capitalization of 443.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
3.38%
5-Day Change
1.97%
1-Month Change
3.54%
3-Month Change
37.07%
6-Month Change
-4.40%
Year-to-Date (YTD) Change
1.20%
1-Year Change
-33.89%
3-Year Change
-18.23%
5-Year Change
-45.64%
All-Time (Max) Change
-41.48%

Contact Information

949 284 4555
520 Newport Center Drive, Newport Beach, CA, 92660

Company Facts

372 Employees
IPO DateFeb 8, 2018
CountryUS
Actively Trading

Frequently Asked Questions